Search

Your search keyword '"Laboratoire de Biochimie [CHRU Nîmes]"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Laboratoire de Biochimie [CHRU Nîmes]" Remove constraint Author: "Laboratoire de Biochimie [CHRU Nîmes]" Database OpenAIRE Remove constraint Database: OpenAIRE
33 results on '"Laboratoire de Biochimie [CHRU Nîmes]"'

Search Results

1. Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study

2. Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay

3. The quantitative ultrasound method for assessing low bone mass in women with anorexia nervosa

4. Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects

5. Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit

6. Theme 4 In vivo experimental models

7. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study

8. Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?

9. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis

10. Liquid chromatography–tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction

11. Relevance of total PSA and free PSA prescriptions

12. Suivi thérapeutique pharmacologique du 5-fluorouracile : mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer

13. 5-fluorouracil therapeutic drug monitoring Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer

14. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

15. Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines:mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx

16. Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability

17. Intermediate C9orf72 repeat numbers are not ALS risk factors

18. Amyotrophic lateral sclerosis in Huntington disease gene carrier

19. Les répétitions intermédiaires GGGGCC du gène C9ORF72 ne sont pas un facteur de risque de SLA

20. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture

21. Cancer genomics guide clinical practice in personalized medicine

22. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer

23. Prevention of 5-fluorouracil–induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing

24. Mystery Case: CSF-1R mutation is a cause of intracranial cerebral calcifications, cysts, and leukoencephalopathy: [RETRACTED]

25. Liver X receptors: from cholesterol regulation to neuroprotection—a new barrier against neurodegeneration in amyotrophic lateral sclerosis?

26. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients

27. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis

28. Living Lab MACVIA Handicap

29. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations

30. Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination

31. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience

32. Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Lung Carcinoma [ERMETIC] Project-Part 1)

33. MiniSOX9, a dominant-negative variant in colon cancer cells

Catalog

Books, media, physical & digital resources